Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno Therapeutics Inc.

Division of Celgene Corp.
www.junotherapeutics.com

Latest From Juno Therapeutics Inc.

China's Draft Cell Therapy Guidelines Draws Concern From Industry

New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.

China Gene Therapy

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

Financing StartUps and SMEs

J.P. Morgan Roundtable: Making Deals And Managing Alliances As Technologies Advance

Part 2: Scrip spoke with companies working on cell and gene therapies and novel neurology approaches during the J.P. Morgan Healthcare Conference about the dos and don'ts of deal-making as they advance innovative programs into the clinic and beyond.

Deals StartUps and SMEs

Celgene Gives Reassurances That Key Products And Programs Remain On Track

Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.

Sales & Earnings Research and Development Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register